Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.5320
+0.0306 (6.10%)
At close: Jul 25, 2025, 4:00 PM
0.5300
-0.0020 (-0.38%)
After-hours: Jul 25, 2025, 6:28 PM EDT

Company Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.

The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity.

Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings logo
CountryUnited States
Founded2012
IPO DateJul 30, 2021
IndustryBiotechnology
SectorHealthcare
Employees106
CEOTalat Imran

Contact Details

Address:
2051 Ringwood Avenue
San Jose, California 95131
United States
Phone408 457 3700
Websiteranitherapeutics.com

Stock Details

Ticker SymbolRANI
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$11.00
CIK Code0001856725
CUSIP Number753018100
ISIN NumberUS7530181004
SIC Code2834

Key Executives

NamePosition
Talat ImranChief Executive Officer and Director
Mir A. ImranExecutive Chairman
Svai S. SanfordChief Financial Officer
Dr. Mir HashimChief Scientific Officer
Alireza JavadiVice President of Technical Operations
Bella VazquezVice President of Human Resources
Kate McKinley M.B.A.Chief Business Officer
Betsy GutierrezSenior Vice President of Quality Assurance
Arvinder DhallaVice President of Clinical Development

Latest SEC Filings

DateTypeTitle
Jul 23, 2025SCHEDULE 13G/AFiling
Jul 17, 2025SCHEDULE 13GFiling
Jul 16, 20258-KCurrent Report
Jul 16, 2025424B5Filing
Jul 11, 2025EFFECTNotice of Effectiveness
Jul 11, 2025424B5Filing
Jul 10, 2025DEF 14CFiling
Jul 3, 2025S-3Registration statement under Securities Act of 1933
Jun 30, 2025PRE 14CFiling
Jun 26, 20258-KCurrent Report